Compare CLBK & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLBK | TNGX |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2017 | 2020 |
| Metric | CLBK | TNGX |
|---|---|---|
| Price | $18.16 | $12.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $17.00 | $14.33 |
| AVG Volume (30 Days) | 251.6K | ★ 2.4M |
| Earning Date | 05-04-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | N/A | ★ $42,069,000.00 |
| Revenue This Year | $3.97 | $52.63 |
| Revenue Next Year | $11.43 | N/A |
| P/E Ratio | $35.82 | ★ N/A |
| Revenue Growth | N/A | ★ 15.17 |
| 52 Week Low | $12.64 | $1.04 |
| 52 Week High | $18.87 | $13.48 |
| Indicator | CLBK | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 54.92 |
| Support Level | $17.82 | $12.12 |
| Resistance Level | $18.67 | $13.18 |
| Average True Range (ATR) | 0.62 | 0.74 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 73.93 | 52.16 |
Columbia Financial Inc is a federally chartered savings bank that serves the financial needs of depositors and the local community as a community-minded, customer service-focused institution. It offers traditional financial services to businesses and consumers. It attracts deposits from the general public and uses those funds to originate a variety of loans, including multifamily and commercial real estate loans, commercial business loans, one-to-four family real estate loans, construction loans, home equity loans and advances, and other consumer loans, and also offers a broad range of insurance products, investment solutions, and wealth management services.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.